Psilocybin Could be Key to Helping Millions of People with Eating Disorders December 31, 2020 - Baystreet.ca With clinical trials supporting psychedelics, like psilocybin mushrooms for the treatment of obsessive-compulsive disorder, PTSD, opioid addiction, alcoholism, depression and anxiety, it’s only a matter of time before big pharmaceutical companies begin to invest heavily, and incorporate psychedelics into their own drug pipelines. In fact, in a new study from JAMA Psychiatry, it was found that psilocybin “worked better than the usual antidepressant medications,” as noted by NPR. Outside of those issues, psilocybin may also be useful in treating eating disorders. All because psilocybin activates serotonin receptors, or "nature's own appetite suppressant," as noted by Psychology Today. "This powerful brain chemical curbs cravings and shuts off appetite. It makes you feel satisfied even if your stomach is not full. The result is eating less and losing weight." With the psilocybin story gaining momentum, some of the top companies to keep an eye on include Better Plant Sciences Inc. (CSE:PLNT)(OTC:VEGGF), HAVN Life Sciences Inc. (CSE:HAVN), Field Trip Health Ltd. (CSE:FTRP)(OTC:FTRPF), Numinus Wellness Inc. (TSXV:NUMI)(OTC:LKYSF), and Mydecine Innovations Group Inc. (CSE:MYCO)(OTC:MYCOF). Better Plant Sciences Inc. (CSE:PLNT) (OTC:VEGGF) BREAKING NEWS: Better Plant Sciences Inc. is pleased to announce that its partially owned subsidiary NeonMind Biosciences Inc. has successfully completed the maximum offering for its initial public offering of 46,000,000 units of NeonMind at a price to the public of $0.10 per Unit, including 6,000,000 in additional Units pursuant to the exercise in full of the over-allotment option. The gross proceeds from the IPO, before deducting agent fees and estimated offering expenses, were $4.6 million. NeonMind’s common shares were listed on the Canadian Securities Exchange on December 29, 2020 and were immediately halted pending the closing of the IPO. Trading of NeonMind’s common shares on the Exchange will resume at market open on Monday, January 4, 2021 under the ticker symbol “NEON”. Each Unit consists of one common share of NeonMind and one share purchase warrant to purchase one additional common share of NeonMind at a price of $0.20 per share until December 30, 2021. Pursuant to an agency agreement dated December 8, 2020, Mackie Research Capital Corporation acted as agent for NeonMind in connection with the IPO. NeonMind paid the Agent and members of its selling group a cash commission equal to 10% of the gross proceeds of the IPO and granted the Agent and members of its selling group non-transferable warrants to purchase up to an aggregate of 4,600,000 units in NeonMind for $0.10 per unit until December 30, 2022, with each unit consisting of one common share of NeonMind and one share purchase warrant to purchase one additional NeonMind common share at a price of $0.20 per share until December 30, 2022. NeonMind also paid the Agent a corporate finance fee of $45,000 plus GST, and reimbursed the Agent for its legal fees and reasonable expenses. NeonMind expects to use the proceeds from the IPO to complete its preclinical trial using psilocybin and complete protocols for its planned phase 2 human clinical trial, as well as to market its recently launched line of medicinal mushroom coffees. After completion of the IPO, NeonMind now has 112,430,500 common shares issued and outstanding on a non-diluted basis, of which 51,713,500 common shares will be subject to escrow. Better Plant currently owns 33,313,500 NeonMind Shares out of 112,430,500 NeonMind common shares currently issued and outstanding. Better Plant also owns 55,000,0000 warrants to purchase NeonMind common shares at $0.20 per share until May 6, 2022. The NeonMind shares and warrants owned by Better Plant are subject to an escrow agreement whereby the securities will be released in tranches over a 35 month period, beginning 30 days after December 29, 2020. Currently, Better Plant owns approximately 29.6% of the outstanding and issued NeonMind common shares on a non-diluted basis. The listing of NeonMind on the Exchange will not affect the listing of Better Plant and Better Plant’s common stock will continue to trade on the Exchange under the ticker symbol “PLNT”, and continue to trade on the OTCQB under the ticker symbol “VEGGF”. Other related developments from around the markets include: HAVN Life Sciences Inc. (CSE:HAVN) is pleased to announce that it has entered into an agreement with Eight Capital, pursuant to which Eight Capital has agreed to buy, on a bought deal basis, 4,673,000 units at a price of $1.07 per Unit, for gross proceeds of approximately $5,000,100. Each Unit will consist of one common share in the capital of the Company (a “Share”) and one warrant, with each Warrant entitling the holder thereof to purchase one additional Share at an exercise price of $1.34 for a period of 36 months from the date of issuance. The Offering is expected to close on or about January 8, 2021 and is subject to the Company receiving all necessary regulatory approvals. The Company has agreed to grant Eight Capital an over-allotment option to purchase up to an additional 15% of the Units at the Issue Price, exercisable in whole or in part, at any time on or prior to the date that is 30 days following the closing of the Offering. If this option is exercised in full, an additional approximately $750,000 will be raised pursuant to the Offering and the aggregate proceeds of the Offering will be approximately $5,750,000. Field Trip Health Ltd. (CSE:FTRP)(OTC:FTRPF), a global leader in the development and delivery of psychedelic therapies, and WHOOP, the human performance company, announced a partnership whereby Field Trip will be using WHOOP Strap 3.0 to measure the biometric effects of Field Trip’s psychedelic therapies. Field Trip, which is opening Field Trip Health centers across North America and Europe for the delivery of psychedelic therapies, plans to conduct an observational study to assess whether Field Trip’s ketamine-assisted therapies, which have demonstrated significant efficacy in treating mental health conditions such as depression, anxiety and PTSD, translate into improvements in physical health through a variety of biometric measures collected via WHOOP Strap 3.0 including heart rate variability (HRV), resting heart rate, and overall sleep quality. Field Trip procured WHOOP products and access to additional data insights via a research partnership and enterprise program. Numinus Wellness Inc. (TSXV:NUMI)(OTC:LKYSF), a company creating an ecosystem of health solutions centered around developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies, is pleased to announce that it has closed its previously announced bought deal public offering of units through Canaccord Genuity Corp. and Eight Capital pursuant to a short form prospectus dated December 21, 2020. Pursuant to the Offering, the Company issued 25,367,850 Units, on an underwritten basis, at the purchase price of $0.68 per Unit, for aggregate gross proceeds to the Company of $17,250,138, which includes the exercise, in full, by the Underwriters of the over-allotment option granted by the Company to purchase an additional 3,308,850 Units at the Offering Price. Mydecine Innovations Group Inc. (CSE:MYCO)(OTC:MYCOF) an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced therapeutic medicine for mainstream use, announced that it has completed its first commercial harvest of 20 kilograms of psilocybin mushrooms at its research and cultivation facility in Jamaica. The Company is now preparing to export the harvest to its Canadian cGMP Facility which has a Health Canada schedule 1 Dealer’s License attached to it, allowing for legal import. “We are pleased to announce the completion of our first commercial harvest of natural psilocybin mushrooms,” said Joshua Bartch, CEO and Chairman of Mydecine. “There is more research needed on these compounds in order to better understand the entourage effect experienced by patients which has shown dramatically effective results compared to single-molecule synthetic psilocybin in preliminary studies. As the industry grows, the need for naturally occurring psilocybin and access to large quantities of these molecules will be paramount and we are excited to be the first to advance this movement at scale.” Legal Disclaimer / Except for the historical information presented herein, matters discussed in this article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Winning Media is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. For making specific investment decisions, readers should seek their own advice. Better Plant Sciences Inc. has paid three thousand five hundred dollars for advertising and marketing services to be distributed by Winning Media. Winning Media is only compensated for its services in the form of cash-based compensation. Winning Media owns ZERO shares of Better Plant Sciences Inc. Please click here for full disclaimer. Contact Information: 2818047972 ty@LifeWaterMedia.com
Psilocybin Could be Key to Helping Millions of People with Eating Disorders December 31, 2020 - Baystreet.ca With clinical trials supporting psychedelics, like psilocybin mushrooms for the treatment of obsessive-compulsive disorder, PTSD, opioid addiction, alcoholism, depression and anxiety, it’s only a matter of time before big pharmaceutical companies begin to invest heavily, and incorporate psychedelics into their own drug pipelines. In fact, in a new study from JAMA Psychiatry, it was found that psilocybin “worked better than the usual antidepressant medications,” as noted by NPR. Outside of those issues, psilocybin may also be useful in treating eating disorders. All because psilocybin activates serotonin receptors, or "nature's own appetite suppressant," as noted by Psychology Today. "This powerful brain chemical curbs cravings and shuts off appetite. It makes you feel satisfied even if your stomach is not full. The result is eating less and losing weight." With the psilocybin story gaining momentum, some of the top companies to keep an eye on include Better Plant Sciences Inc. (CSE:PLNT)(OTC:VEGGF), HAVN Life Sciences Inc. (CSE:HAVN), Field Trip Health Ltd. (CSE:FTRP)(OTC:FTRPF), Numinus Wellness Inc. (TSXV:NUMI)(OTC:LKYSF), and Mydecine Innovations Group Inc. (CSE:MYCO)(OTC:MYCOF). Better Plant Sciences Inc. (CSE:PLNT) (OTC:VEGGF) BREAKING NEWS: Better Plant Sciences Inc. is pleased to announce that its partially owned subsidiary NeonMind Biosciences Inc. has successfully completed the maximum offering for its initial public offering of 46,000,000 units of NeonMind at a price to the public of $0.10 per Unit, including 6,000,000 in additional Units pursuant to the exercise in full of the over-allotment option. The gross proceeds from the IPO, before deducting agent fees and estimated offering expenses, were $4.6 million. NeonMind’s common shares were listed on the Canadian Securities Exchange on December 29, 2020 and were immediately halted pending the closing of the IPO. Trading of NeonMind’s common shares on the Exchange will resume at market open on Monday, January 4, 2021 under the ticker symbol “NEON”. Each Unit consists of one common share of NeonMind and one share purchase warrant to purchase one additional common share of NeonMind at a price of $0.20 per share until December 30, 2021. Pursuant to an agency agreement dated December 8, 2020, Mackie Research Capital Corporation acted as agent for NeonMind in connection with the IPO. NeonMind paid the Agent and members of its selling group a cash commission equal to 10% of the gross proceeds of the IPO and granted the Agent and members of its selling group non-transferable warrants to purchase up to an aggregate of 4,600,000 units in NeonMind for $0.10 per unit until December 30, 2022, with each unit consisting of one common share of NeonMind and one share purchase warrant to purchase one additional NeonMind common share at a price of $0.20 per share until December 30, 2022. NeonMind also paid the Agent a corporate finance fee of $45,000 plus GST, and reimbursed the Agent for its legal fees and reasonable expenses. NeonMind expects to use the proceeds from the IPO to complete its preclinical trial using psilocybin and complete protocols for its planned phase 2 human clinical trial, as well as to market its recently launched line of medicinal mushroom coffees. After completion of the IPO, NeonMind now has 112,430,500 common shares issued and outstanding on a non-diluted basis, of which 51,713,500 common shares will be subject to escrow. Better Plant currently owns 33,313,500 NeonMind Shares out of 112,430,500 NeonMind common shares currently issued and outstanding. Better Plant also owns 55,000,0000 warrants to purchase NeonMind common shares at $0.20 per share until May 6, 2022. The NeonMind shares and warrants owned by Better Plant are subject to an escrow agreement whereby the securities will be released in tranches over a 35 month period, beginning 30 days after December 29, 2020. Currently, Better Plant owns approximately 29.6% of the outstanding and issued NeonMind common shares on a non-diluted basis. The listing of NeonMind on the Exchange will not affect the listing of Better Plant and Better Plant’s common stock will continue to trade on the Exchange under the ticker symbol “PLNT”, and continue to trade on the OTCQB under the ticker symbol “VEGGF”. Other related developments from around the markets include: HAVN Life Sciences Inc. (CSE:HAVN) is pleased to announce that it has entered into an agreement with Eight Capital, pursuant to which Eight Capital has agreed to buy, on a bought deal basis, 4,673,000 units at a price of $1.07 per Unit, for gross proceeds of approximately $5,000,100. Each Unit will consist of one common share in the capital of the Company (a “Share”) and one warrant, with each Warrant entitling the holder thereof to purchase one additional Share at an exercise price of $1.34 for a period of 36 months from the date of issuance. The Offering is expected to close on or about January 8, 2021 and is subject to the Company receiving all necessary regulatory approvals. The Company has agreed to grant Eight Capital an over-allotment option to purchase up to an additional 15% of the Units at the Issue Price, exercisable in whole or in part, at any time on or prior to the date that is 30 days following the closing of the Offering. If this option is exercised in full, an additional approximately $750,000 will be raised pursuant to the Offering and the aggregate proceeds of the Offering will be approximately $5,750,000. Field Trip Health Ltd. (CSE:FTRP)(OTC:FTRPF), a global leader in the development and delivery of psychedelic therapies, and WHOOP, the human performance company, announced a partnership whereby Field Trip will be using WHOOP Strap 3.0 to measure the biometric effects of Field Trip’s psychedelic therapies. Field Trip, which is opening Field Trip Health centers across North America and Europe for the delivery of psychedelic therapies, plans to conduct an observational study to assess whether Field Trip’s ketamine-assisted therapies, which have demonstrated significant efficacy in treating mental health conditions such as depression, anxiety and PTSD, translate into improvements in physical health through a variety of biometric measures collected via WHOOP Strap 3.0 including heart rate variability (HRV), resting heart rate, and overall sleep quality. Field Trip procured WHOOP products and access to additional data insights via a research partnership and enterprise program. Numinus Wellness Inc. (TSXV:NUMI)(OTC:LKYSF), a company creating an ecosystem of health solutions centered around developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies, is pleased to announce that it has closed its previously announced bought deal public offering of units through Canaccord Genuity Corp. and Eight Capital pursuant to a short form prospectus dated December 21, 2020. Pursuant to the Offering, the Company issued 25,367,850 Units, on an underwritten basis, at the purchase price of $0.68 per Unit, for aggregate gross proceeds to the Company of $17,250,138, which includes the exercise, in full, by the Underwriters of the over-allotment option granted by the Company to purchase an additional 3,308,850 Units at the Offering Price. Mydecine Innovations Group Inc. (CSE:MYCO)(OTC:MYCOF) an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced therapeutic medicine for mainstream use, announced that it has completed its first commercial harvest of 20 kilograms of psilocybin mushrooms at its research and cultivation facility in Jamaica. The Company is now preparing to export the harvest to its Canadian cGMP Facility which has a Health Canada schedule 1 Dealer’s License attached to it, allowing for legal import. “We are pleased to announce the completion of our first commercial harvest of natural psilocybin mushrooms,” said Joshua Bartch, CEO and Chairman of Mydecine. “There is more research needed on these compounds in order to better understand the entourage effect experienced by patients which has shown dramatically effective results compared to single-molecule synthetic psilocybin in preliminary studies. As the industry grows, the need for naturally occurring psilocybin and access to large quantities of these molecules will be paramount and we are excited to be the first to advance this movement at scale.” Legal Disclaimer / Except for the historical information presented herein, matters discussed in this article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Winning Media is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. For making specific investment decisions, readers should seek their own advice. Better Plant Sciences Inc. has paid three thousand five hundred dollars for advertising and marketing services to be distributed by Winning Media. Winning Media is only compensated for its services in the form of cash-based compensation. Winning Media owns ZERO shares of Better Plant Sciences Inc. Please click here for full disclaimer. Contact Information: 2818047972 ty@LifeWaterMedia.com